{
    "clinical_study": {
        "@rank": "149739", 
        "acronym": "OPuS-1", 
        "arm_group": [
            {
                "arm_group_label": "BCX4161", 
                "arm_group_type": "Active Comparator", 
                "description": "400 mg TID for 28 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "TID for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic\n      treatment is safe and effective in reducing the number of acute attacks in patients with\n      hereditary angioedema."
        }, 
        "brief_title": "Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hereditary Angioedema", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Clinical and laboratory diagnosis of Hereditary Angioedema Type I or II\n\n          -  An average angioedema attack frequency of 1/week\n\n          -  Acceptable birth control measures\n\n        Key Exclusion Criteria:\n\n          -  Concurrent use of defined treatments for prophylaxis\n\n          -  Pregnancy or breast-feeding\n\n          -  Clinically significant medical condition, laboratory abnormality or medical history"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984788", 
            "org_study_id": "BCX4161-203"
        }, 
        "intervention": [
            {
                "arm_group_label": "BCX4161", 
                "intervention_name": "BCX4161", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Oral Prophylaxis", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Marcus Maurer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Emel Aygoren-Pursun"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Petra Staubach"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morfelden-Walldorf", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Inmaculada Martinez-Saguer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munchen", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Murat Bas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Dr Hilary Longhurst"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Safety and Efficacy of BCX4161 as a Prophylactic Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema", 
        "overall_official": {
            "affiliation": "Charite University, Berlin, Germany", 
            "last_name": "Marcus Maurer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of acute angioedema attacks", 
            "safety_issue": "No", 
            "time_frame": "Over 28 days of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence and severity of adverse events and laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Over 28 days of treatment"
            }, 
            {
                "measure": "Number of attack free days", 
                "safety_issue": "No", 
                "time_frame": "Over 28 days of treatment"
            }, 
            {
                "measure": "Angioedema Quality of Life scores", 
                "safety_issue": "No", 
                "time_frame": "Over 28 days of treatment"
            }, 
            {
                "measure": "Angioedema activity scores", 
                "safety_issue": "No", 
                "time_frame": "Over 28 days of treatment"
            }
        ], 
        "source": "BioCryst Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioCryst Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}